# reload+after+2024-01-21 06:46:50.889023
address1§601 Gateway Blvd
address2§Ste 1250
city§South San Francisco
state§CA
zip§94080
country§United States
phone§415 910 5717
website§https://www.quincetx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
fullTimeEmployees§21
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Dirk  Thye M.D.', 'age': 53, 'title': 'CEO & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 681359, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brendan  Hannah M.B.A.', 'age': 37, 'title': 'Principal Financial Officer, Principal Accounting Officer, Chief Business Officer & COO', 'yearBorn': 1986, 'fiscalYear': 2022, 'totalPay': 504341, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Charles S. Ryan J.D., Ph.D.', 'age': 59, 'title': 'President', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Guenter R. Janhofer M.D., Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stacy  Roughan', 'title': 'Vice President of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mary Ellen Sillivos', 'title': 'Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stewart A. Low Ph.D.', 'title': 'Head of Discovery', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§5
compensationRisk§10
shareHolderRightsRisk§10
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.271
currency§USD
dateShortInterest§1702598400
forwardEps§-3.01
exchange§NMS
quoteType§EQUITY
shortName§Quince Therapeutics, Inc.
longName§Quince Therapeutics, Inc.
firstTradeDateEpochUtc§1557408600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§da44f040-5883-3598-bd5c-37ccfbaf9c2e
gmtOffSetMilliseconds§-18000000
recommendationMean§3.0
recommendationKey§hold
quickRatio§37.162
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
